X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan, effective January 31, 2025. The awards consist of options to purchase 130,117 shares of X4's common stock, granted exclusively to individuals who were not previously X4 employees.
The stock options have a ten-year term and an exercise price of $0.7001 per share, matching X4's closing price on January 31, 2025. The vesting schedule spans four years, with 25% of shares vesting after 12 months and the remaining vesting monthly over the following 36 months, contingent on continued employment. These grants were approved by X4's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, XFOR declined 0.73%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 130,117 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication and being reviewed by the EMA for approval in the EU for the same indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts and operates a research center of excellence in Vienna, Austria. For more information, please visit www.x4pharma.com.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares are included in XFOR's January 2025 inducement awards?
What is the exercise price for XFOR's January 2025 inducement stock options?
What is the vesting schedule for XFOR's January 2025 inducement options?
How long is the term of XFOR's January 2025 inducement stock options?
